Lolis Evangelos D, Kyziridis Dimitrios, Kalakonas Apostolos, Tentes Antonios-Apostolos
Department of Surgery, University Hospital of Ioannina, Ioannina, Greece;
Department of Surgical Oncology, Peritoneal Surface Malignancy Program, Euromedica Kyanos Stavros, Thessaloniki, Greece.
In Vivo. 2025 Sep-Oct;39(5):2832-2841. doi: 10.21873/invivo.14083.
BACKGROUND/AIM: Peritoneal carcinomatosis of recurrent endometrial cancer (EC) is a rare clinical entity with dismal prognosis. The purpose of this study was the presentation of the outcomes of patients with peritoneal carcinomatosis from recurrent endometrial cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
The files of the patients with recurrent EC and peritoneal carcinomatosis treated with CRS and HIPEC between 2000 and 2024 were retrospectively reviewed. Clinical and histopathological variables were correlated to survival, morbidity, and mortality.
CRS plus HIPEC was performed in 23 female patients, mean age 60.4±7.9 (48-75) years. The mean peritoneal cancer index was 10.6±6 (3-39). Complete or near-complete cytoreduction was possible in 82.6% of patients. The incidence of severe morbidity and hospital mortality was 8.68% and 0%, respectively. Recurrence was recorded in 47% of patients. The overall 5- and 10-year survival was 78%. The completeness of cytoreduction score was identified as the single possible prognostic variable of survival.
Complete cytoreduction combined with HIPEC appears to offer significant survival benefit with low morbidity in patients with recurrent EC and peritoneal carcinomatosis.
背景/目的：复发性子宫内膜癌的腹膜癌是一种罕见的临床病症，预后较差。本研究的目的是介绍接受细胞减灭术（CRS）和腹腔内热灌注化疗（HIPEC）治疗的复发性子宫内膜癌腹膜癌患者的治疗结果。
回顾性分析2000年至2024年间接受CRS和HIPEC治疗的复发性子宫内膜癌和腹膜癌患者的病历。将临床和组织病理学变量与生存率、发病率和死亡率进行相关性分析。
23例女性患者接受了CRS联合HIPEC治疗，平均年龄60.4±7.9（48 - 75）岁。平均腹膜癌指数为10.6±6（3 - 39）。82.6%的患者实现了完全或接近完全的细胞减灭。严重并发症的发生率和医院死亡率分别为8.68%和0%。47%的患者出现复发。总体5年和10年生存率为78%。细胞减灭评分的完整性被确定为生存的唯一可能预后变量。
对于复发性子宫内膜癌和腹膜癌患者，完全细胞减灭联合HIPEC似乎能带来显著的生存益处，且发病率较低。
